ADC – ANTIBODY-DRUG CONJUGATES IN ONCOLOGY
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6657Keywords:
Antibody-drug Conjugates, Breast Cancer, Bladder Cancer, Lung CancerAbstract
Background: Antibody-drug conjugates (ADC) are a promising novel therapy for oncology patients as it combines tumor- targeted antibodies with cytotoxic molecules resulting in improved therapeutic outcomes.
Aim: The aim of this article is a thorough analysis of ADC possibilities in oncology focusing on treatment options, side effects of therapies for breast, bladder and lung cancers.
Material and methods: A search of relevant research databases was conducted to identify eligible papers.
Results: Findings reveal ADC to be a promising treatment option as a innovative, more precise form of therapy.
References
Chen, B., Zheng, X., Wu, J., Chen, G., Yu, J., Xu, Y., Wu, W. K. K., Tse, G. M. K., To, K. F., & Kang, W. (2025). Antibody-drug conjugates in cancer therapy: Current landscape, challenges, and future directions. Mol Cancer, 24(1), 279. https://doi.org/10.1186/s12943-025-02489-2
Mansinho, A., Albuquerque, J., Barigazzi, C., & Calvo, E. (2026). Antibody-drug conjugates in cancer treatment: From molecular design to clinical implementation. Lancet Reg Health Eur, 64, 101634. https://doi.org/10.1016/j.lanepe.2026.101634
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., Yu, Z., Zhao, L., He, M., Wang, Y., Fu, C., Wei, M., & Yu, L. (2025). Antibody-drug conjugates (ADCs): Current and future biopharmaceuticals. J Hematol Oncol, 18(1), 51. https://doi.org/10.1186/s13045-025-01704-3
Peters, C., & Brown, S. (2015). Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep, 35(4). https://doi.org/10.1042/BSR20150089
Tsuchikama, K., & An, Z. (2018). Antibody-drug conjugates: Recent advances in conjugation and linker chemistries. Protein Cell, 9(1), 33–46. https://doi.org/10.1007/s13238-016-0323-0
Conilh, L., Sadilkova, L., Viricel, W., & Dumontet, C. (2023). Payload diversification: A key step in the development of antibody-drug conjugates. J Hematol Oncol, 16(1), 3. https://doi.org/10.1186/s13045-022-01397-y
Albino, S. N., Domingos, M. M., Pacheco, T. R., Carvalho, A. S., Castanho, M. A. R.B., & Cavaco, M. (2026). Linker design in antibody-drug conjugates: Balancing stability and drug release. Pharmaceutics, 18(8). https://doi.org/10.3390/pharmaceutics18080954
Ashman, N., Bargh, J. D., & Spring, D. R. (2022). Non-internalising antibody-drug conjugates. Chem Soc Rev, 51(22), 9182–9202. https://doi.org/10.1039/d2cs00446a
Giugliano, F., Corti, C., Tarantino, P., Michelini, F., & Curigliano, G. (2022). Bystander effect of antibody-drug conjugates: Fact or fiction?. Curr Oncol Rep, 24(7), 809–817. https://doi.org/10.1007/s11912-022-01266-4
Wang, Y., Cheng, X., Li, X., Chen, W., Zhang, X., & Liu, Y. (2025). Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity. Crit Rev Oncol Hematol, 216, 104979. https://doi.org/10.1016/j.critrevonc.2025.104979
Khera, E., Dong, S., Huang, H., de Bever, L., van Delft, F. L., & Thurber, G. M. (2022). Cellular-resolution imaging of bystander payload tissue penetration from antibody-drug conjugates. Mol Cancer Ther, 21(2), 310–321. https://doi.org/10.1158/1535-7163.MCT-21-0580
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023). Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel), 15(3). https://doi.org/10.3390/cancers15030713
Su, Z., Xiao, D., Xie, F., Liu, L., Wang, Y., Fan, S., Zhou, X., & Li, S. (2021). Antibody-drug conjugates: Recent advances in linker chemistry. Acta Pharm Sin B, 11(12), 3889–3907. https://doi.org/10.1016/j.apsb.2021.03.042
Riccardi, F., Dal Bo, M., Macor, P., & Toffoli, G. (2023). A comprehensive overview on antibody-drug conjugates: From the conceptualization to cancer therapy. Front Pharmacol, 14, 1274088. https://doi.org/10.3389/fphar.2023.1274088
Zhu, Y., Liu, K., Wang, K., & Zhu, H. (2023). Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis. Cancer, 129(2), 283–295. https://doi.org/10.1002/cncr.34507
Sung, H., Filho, A. M., Laversanne, M., Ferlay, J., Siegel, R. L., Soerjomataram, I., Jemal, A., & Bray, F. (2026). Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin, 76(4), e70090. https://doi.org/10.3322/caac.70090
Li, N., Yang, L., Zhao, Z., Du, T., Liang, G., & Tang, J. (2025). Antibody-drug conjugates in breast cancer: Current evidence and future directions. Exp Hematol Oncol, 14(1), 41. https://doi.org/10.1186/s40164-025-00632-9
Mark, C., Lee, J. S., Cui, X., & Yuan, Y. (2023). Antibody-drug conjugates in breast cancer: Current status and future directions. Int J Mol Sci, 24(18). https://doi.org/10.3390/ijms241813726
Wali, A. F., El-Tanani, M., Talath, S., Rabbani, S. A., Rangraze, I. R., Satyam, S. M., Avagimyan, A., Hoffmann, K., Ilias, I., Ispas, S., Viviana, M., Paczkowska, A., & Rizzo, M. (2025). Antibody-drug conjugates and beyond: Next-generation targeted therapies for breast cancer. Cancers (Basel), 17(24). https://doi.org/10.3390/cancers17243943
Chang, H. L., Schwettmann, B., McArthur, H. L., & Chan, I. S. (2023). Antibody-drug conjugates in breast cancer: Overcoming resistance and boosting immune response. J Clin Invest, 133(18). https://doi.org/10.1172/JCI172156
Dyrskjøt, L., Hansel, D. E., Efstathiou, J. A., Knowles, M. A., Galsky, M. D., Teoh, J., & Theodorescu, D. (2023). Bladder cancer. Nat Rev Dis Primers, 9(1), 58. https://doi.org/10.1038/s41572-023-00468-9
Lopez-Beltran, A., Cookson, M. S., Guercio, B. J., & Cheng, L. (2024). Advances in diagnosis and treatment of bladder cancer. BMJ, 384, e076743. https://doi.org/10.1136/bmj-2023-076743
Zhang, F., & Li, S. (2025). Antibody-drug conjugates as game changers in bladder cancer: Current progress and future directions. Front Immunol, 16, 1591191. https://doi.org/10.3389/fimmu.2025.1591191
McGregor, B., O'Donnell, P. H., Balar, A., Petrylak, D., Rosenberg, J., Yu, E. Y., Quinn, D. I., Heath, E. I., Campbell, M., Hepp, Z., McKay, C., Steinberg, J., Regnault, A., Mazerolle, F., & Galsky, M. D. (2022). Health-related quality of life of patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin after platinum and PD-1/PD-L1 inhibitor therapy: Results from cohort 1 of the phase 2 EV-201 clinical trial. Eur Urol, 81(5), 515–522. https://doi.org/10.1016/j.eururo.2022.01.032
Tagawa, S. T., Balar, A. V., Petrylak, D. P., Kalebasty, A. R., Loriot, Y., Fléchon, A., Jain, R. K., Agarwal, N., Bupathi, M., Barthelemy, P., Beuzeboc, P., Palmbos, P., Kyriakopoulos, C. E., Pouessel, D., Sternberg, C. N., Hong, Q., Goswami, T., Itri, L. M., & Grivas, P. (2021). TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol, 39(22), 2474–2485. https://doi.org/10.1200/JCO.20.03489
Wang, D., Cao, M., Zhang, Y., Bi, L., Chen, M., Ni, M., Zheng, Q., Yao, K., Liu, Z., Yang, X., Shi, Y., Wu, Z., & An, X. (2025). RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: A multicenter, real-world, retrospective study. BMC Cancer, 25(1), 812. https://doi.org/10.1186/s12885-025-14154-4
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024). Non-small-cell lung cancer. Nat Rev Dis Primers, 10(1), 71. https://doi.org/10.1038/s41572-024-00551-9
Riely, G. J., Wood, D. E., Aisner, D. L., Axtell, A. L., Bauman, J. R., Bharat, A., Chang, J. Y., Desai, A., Dilling, T. J., Dowell, J., Durm, G. A., Gettinger, S., Grotz, T. E., Gubens, M. A., Juloori, A., Lackner, R. P., Lanuti, M., Levy, B., Lin, J., … Hang, L. (2026). Non-small cell lung cancer, version 4.2026, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 24(4). https://doi.org/10.6004/jnccn.2026.0017
Debieuvre, D., Macouillard, P., Quantin, X., Berktas, M., Girard, N., Audigier-Valette, C., Filleron, T., Musilli, S., Bosquet, L., & Pérol, M. (2026). Retrospective analysis of HER2 testing, treatment patterns, and clinical outcomes in patients with locally advanced or metastatic NSCLC with HER2 mutations in France. Cancer Med, 15(6), e71975. https://doi.org/10.1002/cam4.71975
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L., Saltos, A. N., Felip, E., Pacheco, J. M., Pérol, M., Paz-Ares, L., Saxena, K., Shiga, R., Cheng, Y., Acharyya, S., Vitazka, P., Shahidi, J., … Jänne, P. A. (2022). Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med, 386(3), 241–251. https://doi.org/10.1056/NEJMoa2112431
Goto, K., Goto, Y., Kubo, T., Ninomiya, K., Kim, S. W., Planchard, D., Ahn, M. J., Smit, E. F., de Langen, A. J., Pérol, M., Pons-Tostivint, E., Novello, S., Hayashi, H., Shimizu, J., Kim, D. W., Kuo, C. H., Yang, J. C., Pereira, K., Cheng, F. C., … Jänne, P. A. (2023). Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: Primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol, 41(31), 4852–4863. https://doi.org/10.1200/jco.23.01361
Ahn, M. J., Lisberg, A., Goto, Y., Sands, J., Hong, M. H., Paz-Ares, L., Pons-Tostivint, E., Pérol, M., Felip, E., Sugawara, S., Hayashi, H., Cho, B. C., Blumenschein, G., Jr., Shum, E., Lee, J. S., Heist, R. S., Cornelissen, R., Chang, W. C., Kowalski, D., … Okamoto, I. (2025). A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. J Thorac Oncol, 20(11), 1669–1682. https://doi.org/10.1016/j.jtho.2025.06.002
Camidge, D. R., Bar, J., Horinouchi, H., Goldman, J., Moiseenko, F., Filippova, E., Cicin, I., Ciuleanu, T., Daaboul, N., Liu, C., Bradbury, P., Moskovitz, M., Katgi, N., Tomasini, P., Zer, A., Girard, N., Cuppens, K., Han, J. Y., Wu, S. Y., … Lu, S. (2024). Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial. J Clin Oncol, 42(25), 3000–3011. https://doi.org/10.1200/jco.24.00720
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022). Antibody drug conjugate: The "biological missile" for targeted cancer therapy. Signal Transduct Target Ther, 7(1), 93. https://doi.org/10.1038/s41392-022-00947-7
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019). Antibody-drug conjugates for cancer. Lancet, 394(10200), 793–804. https://doi.org/10.1016/S0140-6736(19)31774-X
Schurmans, S., & Moës, B. (2026). CD19 structure, expression, and signaling: From basic mechanisms to therapeutic targeting. Adv Biol Regul, 99, 101116. https://doi.org/10.1016/j.jbior.2025.101116
Caimi, P. F., Ai, W., Alderuccio, J. P., Ardeshna, K. M., Hamadani, M., Hess, B., Kahl, B. S., Radford, J., Solh, M., Stathis, A., Zinzani, P. L., Havenith, K., Feingold, J., He, S., Qin, Y., Ungar, D., Zhang, X., & Carlo-Stella, C. (2021). Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol, 22(6), 790–800. https://doi.org/10.1016/S1470-2045(21)00139-X
Esapa, B., Jiang, J., Cheung, A., Chenoweth, A., Thurston, D. E., & Karagiannis, S. N. (2023). Target antigen attributes and their contributions to clinically approved antibody-drug conjugates (ADCs) in haematopoietic and solid cancers. Cancers (Basel), 15(6). https://doi.org/10.3390/cancers15061845
Doody, G. M., Justement, L. B., Delibrias, C. C., Matthews, R. J., Lin, J., Thomas, M. L., & Fearon, D. T. (1995). A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science, 269(5221), 242–4. https://doi.org/10.1126/science.7618087
Kang, C. (2021). Moxetumomab pasudotox in hairy cell leukaemia: A profile of its use. Clin Drug Investig, 41(9), 829–834. https://doi.org/10.1007/s40261-021-01069-8
Kuruvilla, D., Chia, Y. L., Balic, K., Yao, N. S., Kreitman, R. J., Pastan, I., Li, X., Standifer, N., Liang, M., Tseng, C. M., Faggioni, R., & Roskos, L. (2020). Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia. Br J Clin Pharmacol, 86(7), 1367–1376. https://doi.org/10.1111/bcp.14250
Zhang, H., Yan, Y., Yi, S., & Sun, Q. (2025). Advancements in targeting CD30 for lymphoma therapy: A historical perspective and future directions. Expert Rev Hematol, 18(5), 373–386. https://doi.org/10.1080/17474086.2025.2492936
Montalbano, M. C., Micillo, M., Deaglio, S., & Vaisitti, T. (2026). Antibody-drug conjugates in hematological malignancies: Current landscape and future perspectives. Int J Mol Sci, 27(2). https://doi.org/10.3390/ijms27021025
Hills, R. K., Castaigne, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S., Othus, M., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., Cahn, J. Y., Récher, C., Chilton, L., Moorman, A. V., & Burnett, A. K. (2014). Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol, 15(9), 986–96. https://doi.org/10.1016/S1470-2045(14)70281-5
Maiolo, E., Bellesi, S., Campana, F., Iacovelli, C., Malafronte, R., Schiaffini, G., Alma, E., Bellisario, F., Viscovo, M., D'Innocenzo, S., Toscano, A., D'Alò, F., De Stefano, V., Larocca, L. M., & Hohaus, S. (2024). Heterogeneous surface CD79b expression in aggressive B-cell lymphomas assessed by flow cytometry on lymph node biopsies. Cancers (Basel), 16(23). https://doi.org/10.3390/cancers16233968
Sehn, L. H., Herrera, A. F., Flowers, C. R., Kamdar, M. K., McMillan, A., Hertzberg, M., Assouline, S., Kim, T. M., Kim, W. S., Ozcan, M., Hirata, J., Penuel, E., Paulson, J. N., Cheng, J., Ku, G., & Matasar, M. J. (2020). Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol, 38(2), 155–165. https://doi.org/10.1200/JCO.19.00172
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Jędrzej Kowalski, Dominik Szymczak, Olaf Zołotar, Marcin Szczepanik, Natalia Pociej, Jakub Senko, Joanna Kulpa, Zofia Suchanek, Wojciech Pociej, Krzysztof Dzierbunowicz
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
